News ADC Therapeutics slumps on cancer drug safety scare Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
News ASCO26: Celcuity punished as trial disappoints investors Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.
News ASCO26: In vivo CAR-Ts in the spotlight Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.
News ASCO26: After negative adcomm, AZ builds case for oral SERD AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.
News Abivax slides on phase 3 data in ulcerative colitis Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.